[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71, 209−49. doi:  10.3322/caac.21660
[2] Bish A, Ramirez A, Burgess C, et al. Understanding why women delay in seeking help for breast cancer symptoms. J Psychosom Res, 2005; 58, 321−6. doi:  10.1016/j.jpsychores.2004.10.007
[3] McKinney SM, Sieniek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. Nature, 2020; 577, 89−94. doi:  10.1038/s41586-019-1799-6
[4] Maruvada P, Wang W, Wagner PD, et al. Biomarkers in molecular medicine: cancer detection and diagnosis. BioTechniques, 2005; 38, S9−15. doi:  10.2144/05384SU04
[5] Zou RY, Loke SY, Tang YC, et al. Development and validation of a circulating microRNA panel for the early detection of breast cancer. Br J Cancer, 2022; 126, 472−81. doi:  10.1038/s41416-021-01593-6
[6] Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 2006; 6, 259−69. doi:  10.1038/nrc1840
[7] Hajian-Tilaki K. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform, 2014; 48, 193−204. doi:  10.1016/j.jbi.2014.02.013
[8] Salim B, Athira MV, Kandaswamy A, et al. Microfluidic device for novel breast cancer screening by blood test using miRNA beacon probe. Biomed Microdevices, 2017; 19, 89. doi:  10.1007/s10544-017-0230-z